Is ALLR or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% Liminatus Pharma N/A N/A -256.58%

Do analysts rate NCEL or LIMN?

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 578.47%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities analysts clearly believe NLS Pharmaceutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, NCEL or LIMN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A

Is NCEL or LIMN more profitable?

Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Liminatus Pharma N/A N/A -256.58%

Do analysts rate CMMB or LIMN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CMMB or LIMN?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A

Is CMMB or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% Liminatus Pharma N/A N/A -256.58%

Do analysts recommend LIMN or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 645.16%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer LIMN or ENLV?

Enlivex Therapeutics has a consensus price target of $247.50, indicating a potential upside of 30,414.12%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enlivex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, LIMN or ENLV?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A

Is LIMN or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Liminatus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -256.58% Enlivex Therapeutics N/A 248.08% 206.39%

Liminatus Pharma (LIMN) Competitors

$3.33 -0.18 (-5.13%)

Closing price 09/16/2026 03:59 PM Eastern

Extended Trading

$3.48 +0.15 (+4.35%)

As of 07:31 AM Eastern

Compare

LIMN vs. ALLR, NCEL, CMMB, DYAI, and ENLV

Should you buy Liminatus Pharma stock or one of its competitors? Liminatus Pharma's main competitors and comparable companies include Allarity Therapeutics (ALLR), NLS Pharmaceutics (NCEL), Chemomab Therapeutics (CMMB), Dyadic International (DYAI), and Enlivex Therapeutics (ENLV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Liminatus Pharma compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Allarity Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.3, suggesting that its share price is 430% more volatile than the broader market.

Liminatus Pharma's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
Liminatus Pharma	N/A	N/A	-256.58%

Liminatus Pharma has lower revenue, but higher earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	57.43	-$11.23M	-$0.78	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 787.45%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Allarity Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Allarity Therapeutics had 4 more articles in the media than Liminatus Pharma. MarketBeat recorded 6 mentions for Allarity Therapeutics and 2 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.44 beat Allarity Therapeutics' score of 0.31 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
Liminatus Pharma	Positive

11.5% of Allarity Therapeutics shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 19.4% of Liminatus Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Allarity Therapeutics beats Liminatus Pharma on 8 of the 14 factors compared between the two stocks.

How does Liminatus Pharma compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Liminatus Pharma	N/A	N/A	-256.58%

NLS Pharmaceutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.3, indicating that its stock price is 430% more volatile than the broader market.

NLS Pharmaceutics currently has a consensus target price of $23.00, indicating a potential upside of 578.47%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities analysts clearly believe NLS Pharmaceutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 2 articles in the media. NLS Pharmaceutics' average media sentiment score of 1.44 equaled Liminatus Pharma'saverage media sentiment score.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Liminatus Pharma	Positive

Summary

NLS Pharmaceutics beats Liminatus Pharma on 5 of the 6 factors compared between the two stocks.

How does Liminatus Pharma compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Liminatus Pharma had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for Chemomab Therapeutics. Liminatus Pharma's average media sentiment score of 1.44 beat Chemomab Therapeutics' score of 0.93 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Chemomab Therapeutics	Positive
Liminatus Pharma	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

46.1% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 19.4% of Liminatus Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A

Chemomab Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.3, suggesting that its share price is 430% more volatile than the broader market.

Liminatus Pharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
Liminatus Pharma	N/A	N/A	-256.58%

Summary

Liminatus Pharma beats Chemomab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Liminatus Pharma compare to Dyadic International?

Liminatus Pharma (NASDAQ:LIMN) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

In the previous week, Dyadic International had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 3 mentions for Dyadic International and 2 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.44 beat Dyadic International's score of 1.42 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Positive
Dyadic International	Positive

Dyadic International has higher revenue and earnings than Liminatus Pharma. Dyadic International is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A
Dyadic International	$3.09M	5.22	-$7.36M	-$0.23	N/A

Liminatus Pharma has a beta of 5.3, suggesting that its share price is 430% more volatile than the broader market. Comparatively, Dyadic International has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 645.16%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Liminatus Pharma has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Liminatus Pharma's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Dyadic International	-201.43%	-2,920.31%	-84.77%

28.0% of Dyadic International shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Dyadic International beats Liminatus Pharma on 10 of the 15 factors compared between the two stocks.

How does Liminatus Pharma compare to Enlivex Therapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Enlivex Therapeutics has a consensus price target of $247.50, indicating a potential upside of 30,414.12%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Liminatus Pharma is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

Enlivex Therapeutics' return on equity of 248.08% beat Liminatus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-256.58%
Enlivex Therapeutics	N/A	248.08%	206.39%

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Liminatus Pharma has a beta of 5.3, suggesting that its stock price is 430% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

In the previous week, Liminatus Pharma had 1 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 2 mentions for Liminatus Pharma and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 1.87 beat Liminatus Pharma's score of 1.44 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Liminatus Pharma	Positive
Enlivex Therapeutics	Very Positive

Summary

Enlivex Therapeutics beats Liminatus Pharma on 11 of the 14 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIMN vs. The Competition

Export

Metric	Liminatus Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.71M	$3.84B	$7.22B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	-0.14	14.33	273.86	25.33
Price / Sales	N/A	1,412.17	643.61	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	-0.18	15.13	10.33	6.24
Net Income	-$10.21M	-$22.78M	$3.49B	$358.55M
7 Day Performance	-8.26%	-2.54%	-0.84%	-1.20%
1 Month Performance	-52.90%	-2.87%	-1.37%	-4.26%
1 Year Performance	-95.81%	37.93%	21.13%	5.47%

Liminatus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIMN Liminatus Pharma	0.7264 of 5 stars	$3.33 -5.1%	N/A	-96.3%	$4.71M	N/A	N/A	N/A	Positive News
ALLR Allarity Therapeutics	1.8448 of 5 stars	$1.24 -2.1%	$10.25 +730.0%	-24.0%	$19.65M	$320K	N/A	10
NCEL NLS Pharmaceutics	2.9019 of 5 stars	$3.36 +3.4%	$23.00 +584.5%	-84.0%	$19.42M	N/A	N/A	6	Positive News Short Interest Decrease
CMMB Chemomab Therapeutics	1.2467 of 5 stars	$2.63 -2.4%	N/A	-5.4%	$19.03M	N/A	N/A	20	Gap Up
DYAI Dyadic International	2.6401 of 5 stars	$0.51 -1.7%	$3.00 +494.1%	-59.4%	$18.40M	$1.33M	N/A	7	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIMN) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liminatus Pharma (LIMN) Competitors

LIMN vs. ALLR, NCEL, CMMB, DYAI, and ENLV

How does Liminatus Pharma compare to Allarity Therapeutics?

Summary

How does Liminatus Pharma compare to NLS Pharmaceutics?

Summary

How does Liminatus Pharma compare to Chemomab Therapeutics?

Summary

How does Liminatus Pharma compare to Dyadic International?

Summary

How does Liminatus Pharma compare to Enlivex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liminatus Pharma (LIMN) Competitors

LIMN vs. ALLR, NCEL, CMMB, DYAI, and ENLV

How does Liminatus Pharma compare to Allarity Therapeutics?

Which has more risk & volatility, ALLR or LIMN?

Is ALLR or LIMN more profitable?

Which has better earnings and valuation, ALLR or LIMN?

Do analysts prefer ALLR or LIMN?

Does the media prefer ALLR or LIMN?

Do institutionals and insiders believe in ALLR or LIMN?

Summary

How does Liminatus Pharma compare to NLS Pharmaceutics?

Is NCEL or LIMN more profitable?

Which has more risk and volatility, NCEL or LIMN?

Do analysts rate NCEL or LIMN?

Which has higher valuation and earnings, NCEL or LIMN?

Does the media refer more to NCEL or LIMN?

Summary

How does Liminatus Pharma compare to Chemomab Therapeutics?

Does the media favor CMMB or LIMN?

Do analysts rate CMMB or LIMN?

Do insiders and institutionals have more ownership in CMMB or LIMN?

Which has higher earnings and valuation, CMMB or LIMN?

Which has more volatility & risk, CMMB or LIMN?

Is CMMB or LIMN more profitable?

Summary

How does Liminatus Pharma compare to Dyadic International?

Does the media prefer LIMN or DYAI?

Which has higher earnings and valuation, LIMN or DYAI?

Which has more volatility and risk, LIMN or DYAI?

Do analysts recommend LIMN or DYAI?

Is LIMN or DYAI more profitable?

Do insiders and institutionals believe in LIMN or DYAI?

Summary

How does Liminatus Pharma compare to Enlivex Therapeutics?

Do analysts prefer LIMN or ENLV?

Which has preferable valuation and earnings, LIMN or ENLV?

Is LIMN or ENLV more profitable?

Do institutionals & insiders believe in LIMN or ENLV?

Which has more risk & volatility, LIMN or ENLV?

Does the media prefer LIMN or ENLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools